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Abstract: 
Background: In 2005 and 2008, studies reported that cannabis in England 
had become dominated by the sinsemilla (unseeded female) form. The 
average potency (∆9-tetrahydrocannabinol [THC] content) of this material 
had doubled over the previous decade. Cannabis resin then circulating 
contained approximately equal ratios of THC and cannabidiol (CBD), 
whereas sinsemilla was almost devoid of CBD. Despite raised health 
concerns regarding sinsemilla use and the development of psychotic 
disorders, no update on street cannabis potency has been published since 
2008. Methods: A total of 995 seized cannabis samples were acquired from 
the same five constabulary areas included in the 2005 study. The differing 
forms were segregated and a representative 460 samples analyzed to 
assess their cannabinoid content using gas chromatography. Results: The 
resultant median sinsemilla potency of 14.2% THC was similar to that 
observed in 2005 (13.9%). In each case, sinsemilla contained minimal 
CBD. Compared with 2005, resin had significantly higher mean THC (6.3%) 
and lower CBD (2.3%) contents (p < 0.0001). Conclusions: Although the 
average THC concentration in sinsemilla samples across the five 
constabularies has remained stable since 2005, the availability of this 
potent form of cannabis has further increased. Moreover, the now rarer 
resin samples show significantly decreased CBD contents and CBD:THC 
ratios, leaving the United Kingdom’s cannabis street market populated by 
high-potency varieties of cannabis, which may have concerning 
implications for public health. 
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ABSTRACT 
Background: In 2005 and 2008, studies reported that cannabis in England had become dominated by 
the sinsemilla (unseeded female) form. The average potency (Δ9-tetrahydrocannabinol [THC] 
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content) of this material had doubled over the previous decade. Cannabis resin then circulating 
contained approximately equal ratios of THC and cannabidiol (CBD), whereas sinsemilla was almost 
devoid of CBD. Despite raised health concerns regarding sinsemilla use and the development of 
psychotic disorders, no update on street cannabis potency has been published since 2008. Methods: 
A total of 995 seized cannabis samples were acquired from the same five constabulary areas 
included in the 2005 study. The differing forms were segregated and a representative 460 samples 
analyzed to assess their cannabinoid content using gas chromatography. Results: The resultant 
median sinsemilla potency of 14.2% THC was similar to that observed in 2005 (13.9%). In each case, 
sinsemilla contained minimal CBD. Compared with 2005, resin had significantly higher mean THC 
(6.3%) and lower CBD (2.3%) contents (p < 0.0001). Conclusions: Although the average THC 
concentration in sinsemilla samples across the five constabularies has remained stable since 2005, 
the availability of this potent form of cannabis has further increased. Moreover, the now rarer resin 
samples show significantly decreased CBD contents and CBD:THC ratios, leaving the United 
Kingdom’s cannabis street market populated by high-potency varieties of cannabis, which may have 
concerning implications for public health. 
 
 
KEYWORDS: herbal cannabis, sinsemilla, resin, potency, cannabinoid, Δ
9
-tetrahydrocannabinol, 
psychosis, cannabidiol, cannabinol 
 
INTRODUCTION 
In all European countries, across all age groups, cannabis is the most popular illicit drug. The 
prevalence of cannabis use in Europe is approximately five times that of other substances. Home 
Office data indicate that, in England and Wales, cannabis remains the most commonly used illicit 
drug, where it accounted for 109,527 of the 148,553 drug samples seized by police in the financial 
year ending March 2016.
1
  
Many studies have reported the consistent and dose-dependent association between cannabis use 
and increased risk of developing a psychotic disorder.
2-6
 In their 2006 World Drug Report, the United 
Nations Office on Drugs and Crime emphasized the global nature of this problem in a detailed 
chapter titled, “Cannabis: Why We Should Care.”
7
 The European Monitoring Centre on Drugs and 
Drug Addiction (EMCDDA) reported that overall, the number of first-time treatment entrants for 
cannabis problems increased from 45,000 in 2006 to 69,000 in 2014. The causes of the increase in 
the number of treatment entrants are unclear, but they may be linked to changes in the prevalence 
of intensive cannabis use and other factors such as the availability of more harmful and higher 
potency products.
8
 
Within the United Kingdom (UK), the illicit drug commonly exists as either a resin (more commonly 
called hashish in the United States) or as dry herbal material. The resin is made by a range of cultural 
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methods that physically remove and collect the trichomes from the plant. This process in turn 
produces materials of varying color and texture. There are two distinct types of dry herbal material. 
One form is imported into the UK from more southerly countries and contains floral and foliar 
material from outdoor-grown pollinated female plants. This form is commonly referred to as 
traditional herbal cannabis in the UK and as marijuana in the United States. The more frequent type 
of dried-plant material in the UK consists of unpollinated female floral tissue only. It is usually more 
potent and is referred to in this article using the widely used term sinsemilla (a Spanish derivation 
meaning “without seeds”). It is also known by a vast range of colloquial names. This form can be 
grown outdoors in more southerly regions but is predominantly grown in more secure indoor 
locations, in the absence of male plants, using highly technical equipment.  
A study of cannabis potency in England in 2005 indicated that sinsemilla potency (i.e., Δ
9
-
tetrahydrocannabinol [THC] content) had doubled over the previous 10 years. The same study 
indicated that low-potency cannabis resin no longer dominated the market. Resin was found to 
contain THC and cannabidiol (CBD) in varying ratios (averaging approximately 1:1), whereas herbal 
cannabis products almost t tally lacked CBD. As CBD has antipsychotic properties that can moderate 
the effects of THC, the combined shift in use from low-potency resin with CBD to high-potency, 
intensively grown cannabis lacking CBD suggested that the illicit cannabis now circulating was 
potentially more harmful than that in use hitherto.
9,10
  A Home Office survey of UK illicit cannabis 
potency was performed 3 years later on the recommendation of the Medicines & Healthcare 
Products Regulatory Agency (MHRA); it showed that the upward trend in THC content had 
continued, as had the decline in availability of cannabis resin.
11
  
The EMCDDA in 2016 dedicated an entire section to the changes in cannabis potency across the 
European Union, reporting that cannabis grown in Morocco, the long-term main source of resin used 
in the UK and Spain, has changed significantly in recent years. Plant varieties with a higher THC 
content now are now being grown to provide more potent cannabis products to meet the taste of 
European users.
12
 As a result, resin potency has increased in France in recent years,
13
 and resin 
elsewhere in Europe may have followed the same trend. 
The illicit use of cannabis is primarily for recreational purposes, but in 1997 and 1998, the British 
Medical Association
14
 and House of Lords Science and Technology Committee
15
 respectively 
highlighted the common use of illicit cannabis in the UK for medicinal reasons. No legal forms of 
cannabis plant-based medicine then existed. The MHRA has since approved the UK use of the 
medicine Sativex®, containing THC and CBD, to treat spasticity symptoms in multiple sclerosis 
patients for whom other treatments have failed.
16
 However, the National Institute for Health and 
Care Excellence has not authorized it in England as a prescription medicine, funded by the National 
Health Service.
17
 
In the absence of prescription cannabis-based medicines, the use of illicit cannabis for medicinal 
purposes continues in the UK,
18
 with one survey suggesting that 72% of users acquire the substance 
from “dealers.”
19
 Although often efficacious in the management of chronic pain, spasticity, and 
other ailments,
18 
the quality and safety of these materials is never assured. 
In the summary of their 2015 World Drug Report, the United Nations Office on Drugs and Crime 
stated that:  
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there is growing evidence that it is time to change the widespread perception of cannabis as an illicit 
drug without serious health consequences. The current cannabis market is far more complex and 
sophisticated than in the past and there is a far larger variety of cannabis products on the market 
than ever before, some of which appear to be more harmful than their predecessors. Highly potent 
strains of herbal cannabis, such as sinsemilla, which have high THC content (the main psychoactive 
ingredient) coupled with low CBD content (a cannabinoid with anti-psychotic properties), are 
becoming increasingly popular in some markets. Given that there is growing evidence of links 
between cannabis use and some forms of mental illness , these developments may lead to even 
greater morbidity; an issue worthy of close monitoring.
20
 
The mental illness referred to here especially includes the well-established association between 
cannabis use and psychotic disorders6
 
and cognitive deficit.
4 
 
To address this issue, we investigated how cannabis circulating in England has changed since the 
previous surveys conducted in 2005 and 2008. The aim of this study was to quantify the relative 
proportions of sinsemilla, traditional herbal cannabis, and resin being used at the time of police 
arrest.  
 
In fresh plant material, THC, CBD, and other newly formed cannabinoids exist in the cannabinoid 
acid forms, such as tetrahydrocannabidiolic acid, or THCA, and cannabidiolic acid, or CBDA. As the 
plant material ages or is heated (as during gas chromatography [GC]), the acid molecules lose a 
carboxyl moiety. Decarboxylation results in the conversion of the cannabinoid acids into their 
neutral forms (e.g., CBDA→CBD). As is common, this article hereafter refers to the cannabinoids in 
their neutral form only. 
 
METHODS 
Acquisition and identification of samples 
Assistance was sought from the same five constabularies used in the 2005 study, i.e., Derbyshire, 
Kent, London Metropolitan, Merseyside, and Sussex. The police were asked to supply any available 
seized cannabis samples in their property stores. All samples had been seized by police in 2015 (Kent 
and London Metropolitan) or 2016 (Derbyshire, Merseyside, and Sussex). All had been retained at 
ambient temperature in police evidence store rooms, in sealed, airtight, tamper-evident bags, for a 
maximum of 12 months before collection. The materials had been seized from users and suppliers 
“on the street” or during searches of properties involved in cannabis dealing or consumption. The 
materials were assessed visually, using a simple light microscope where necessary, and the form of 
the cannabis sample was established. Mirroring the practice of the Home Office, when recording 
illicit cannabis seizures, all resin types were grouped together as a single category.
1
  
Some samples were accompanied by portable cannabis grinders, used to break herbal cannabis and 
sinsemilla into a suitably friable texture for smoking. More complex grinders included a fine metal 
mesh within the construction. Glandular trichomes dislodged from the plant during grinding could 
fall through this sieve and be collected in a separate chamber within the device. Glandular trichomes 
are the principal or sole site of cannabinoid biosynthesis.
21
 Two grinders were found with sufficient 
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powder to enable analysis. This material is commonly referred to as kief and consists almost entirely 
of glandular trichome resin heads and stalks.  
A total of 995 analyzable cannabis samples were received, 929 of which were sinsemilla. The number 
of sinsemilla samples available from each constabulary ranged from 81 to 349. To give a balanced 
picture of the cannabinoid content of these samples across the constabularies, 80 samples were 
selected at random from each, thereby reducing this number to 400. However, only 6 traditional 
herbal cannabis materials and 58 resin samples were identified, of which 53 were available in 
sufficient quantity for analysis. Due to the small numbers of traditional herbal and resin samples 
available, all were analyzed, along with the powders found in the two herb grinders. While waiting 
for analysis, all samples were deep frozen at −20°C. Mirroring the practice of the cannabis consumer, 
no attempt was made to adjust the moisture level of the dry sample. 
Previous studies on illicit cannabis potency in the UK have included analyses of hash oil. This liquid 
preparation is made by dissolving, and subsequently concentrating, cannabis extracts in an organic 
solvent.
22
 More recently, highly potent solid concentrates called butane hash oils (BHO), produced 
using liquid butane as the solvent, have appeared within the marketplace.
23
 No hash oil or BHO 
samples were identified in seizures by the five constabularies in this study. Many samples seized, 
were found to be a mixture of cannabis and tobacco. All were excluded from this study. 
Approximately 1% of the seized samples, labeled by police as Green Vegetable Material, GVM or 
similar, were not cannabis but were suggested to be so-called “legal highs” consisting of other plant 
species with added synthetic cannabinoid receptor agonists.  
Subsampling and analysis 
Herbal cannabis products are extremely inhomogeneous materials, whereas resin samples are 
substantially more uniform.
24
 Experience of analyzing many thousands of cannabis samples at GW 
Pharmaceuticals supports this view. An analyst would require several subsamples of any one batch 
of seized material to reliably determine the average potency of that batch. For the cannabis user, 
this inhomogeneity means that joints made from any one batch of cannabis are likely to vary in 
potency. In this study, just one replicate from each batch of seized material was analyzed, thereby 
capturing the same potency variability encountered by users. The size of the subsample in each case 
was 250 mg, a typical generous weight of cannabis used in a single joint. On the basis of several 
publications, a report by the EMCDDA stated that, across Europe, typical cannabis contents in a 
single joint was 100 to 260 mg.
23 
Small
25
 reported a Europe-wide range of 0.1 to 0.3 g.  An accurate 
overall median potency for cannabis nationwide was achieved in this study by analyzing a large 
number of separate samples. These were taken at random from each crime scene. Replicating the 
practice of cannabis users, fibrous branch material often needed to be removed from the sample 
and discarded. The remaining floral tissue was then weighed and analyzed by GC. 
Each 250-mg sample of material was placed in a Corning Centristar 50-mL centrifuge tube, to which 
was added 20 mL of ethanol (99.7%) and 5 mL of phenanthrene stock solution (10 mg mL
-1 
in 
ethanol) as an internal standard. The sample was sonicated for 30 minutes and then centrifuged at 
4000 rpm for 5 minutes. The extracts were homogenized and transferred to GC vials. Gas 
chromatographic analyses were performed on an Agilent 7890 GC equipped with an autosampler, a 
flame ionisation detector, and a Zebron ZB—5HT Inferno (Column, 30 meters in length, 0.32 mm 
internal diameter, and 0.25-µm film thickness The oven sample preparation program is summarized 
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in Table 1. The injector and detector temperatures were both 325°C. This process achieved complete 
decarboxylation of the cannabinoids. 
 
The following instrument parameters were employed. Front injector syringe size 10 µL, injection 
volume 1 µL. Front inlet hydrogen pressure 7 psi; heater temperature 325°C; split ratio 50:1; total 
flow 149.5 mL min
-1 
; septum purge flow 3 mL min
-1
; split flow 143.6 mL min
-1
. Front detector FID 
temperature 325°C; hydrogen flow 30 mL min
-1 
; air flow 450 mL min
-1 
; make-up flow 13 mL min
-1
. 
 
Statistical analyses were performed using SAS 9.3 software, from SAS Institute Inc., Campus Drive, 
North Carolina 27513. 
 
RESULTS AND DISCUSSION 
Relative proportion of sinsemilla, traditional herbal and resin 
Annual Home Office reports show that from 1994 to 2000, resin accounted for a steady 70% ± 2% of 
all illicit cannabis seized in England and Wales. Its dominance in the market then started to 
decrease.
26
 In the five constabularies included in this study, the proportion had fallen to 43% by 
2005,
9
 to 31% in 2008
11
 and then to 6% in this latest analysis. In all three potency surveys, the 
London Metropolitan area had the lowest proportion of resin among the five constabularies, and 
perhaps leads a national trend. The precise proportions in each of the individual constabularies are 
shown in Table 2. The fall in resin proportions was similar in the Home Office 2015 records for 
England and Wales overall, which showed resin samples to account for 5% of the seized resin and 
herbal cannabis total.
1
 
The London Metropolitan area was also notable in the 2005 study for having the highest proportion 
of traditional herbal samples. That remained the situation in 2008 and 2015, but in the latter case, 
occurrences were minimal, i.e. 1.4% of the total samples seized. 
Cannabinoid content of sinsemilla 
As in the previous studies, THC contents were highly variable, ranging from 1.9% to 22.5%. The 
median was 14.2%. This finding is similar to that in the same five constabularies in 2004/2005 
(13.9%). The distribution of potency values was also very similar, as seen in Figure 1. Some variation 
was found between the median potencies of the individual constabularies (Derbyshire 13.1%, Kent 
12.5%, Sussex 13.3%, London Metropolitan 15.5% and Merseyside 15.8%). In the 2008 Home Office 
Potency Study, across 23 constabularies, a slightly higher median was recorded: 15.0% THC.  
Although samples varied widely in THC content from ≈ 2% to 24%, a large majority (80% of samples) 
had THC contents within a much narrower range of 10% to 20% THC (Figure 2). Those below 10% 
were visually re-examined after analysis, where possible. In almost all cases, those recording a %THC 
of less than 8% gave visible signs that the material was not of the highest potency. Many were found 
to be residual broken particles left after the bulk of the original deal had been used (sometimes 
called “shake”). Others were poorly grown and processed materials. In a few cases, materials 
showed visible signs of decay. This finding suggests that, at the time of packaging, the vast majority 
of materials were within the 10% and 20% THC range. Had this survey been based on freshly 
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packaged samples only, as is the case with some other surveys, the median potency would probably 
have been at least 1% higher.  
 
Unlike other illicit drugs in powder or tablet form, the visual appearance of sinsemilla enables users 
to at least make an approximate judgement of potency. Although never a reliable way of estimating 
potency, those observers with the ability to make a close visual assessment of trichome density and 
color can make an informed judgement.
10 
 
In a natural setting, cannabis plants exist in three main chemotypes (chemical phenotypes) 
producing predominantly THC, CBD, or a mixture of the two.
27
 Resin has traditionally been made 
using a mixture of all three chemotypes. However, continual selection of high-THC plants, when 
breeding and growing for traditional or sinsemilla herbal cannabis, has resulted in CBD being 
generally absent in these products. None of the 247 sinsemilla samples analyzed in 2004/2005 
contained more than 1% CBD. In this latest study, the dominance of THC continued, but one 
Derbyshire sample was notable for containing 7% THC and 9% CBD. Sinsemilla samples with a mixed 
THC/CBD profile are to be expected on occasions, especially if sourced from a single plant. In a 
previous study, when plants we e grown from packeted seed of 52 commercial varieties and 
analyzed, 48 were entirely the THC chemotype, but seeds in the other four occasionally produced 
plants with the mixed THC/CBD profile. In total, 3% of seeds produced mixed chemotype plants.
28(p 
144)
 None of the four seed packets stated that plants containing significant CBD might arise. In recent 
years, commercially available seeds described as having high CBD levels have been advertised, but 
this availability does not appear to have had a significant effect on the UK illicit cannabis market.  
 
The overall median CBN content of sinsemilla in this latest study was 0.24%. For individual 
constabularies, the median contents were 0.33% for London Met, 0.29% for Merseyside, and 0.28% 
for Kent. For Derby and Sussex, the median was below the quantifiable limit of 0.15%.  
 
 
Cannabinoid content of seeded herbal 
The THC contents of the six seeded herbal samples were similar to that previously reported (median 
[range], 3.5% [1.8%–5.7%]). CBD levels were below the quantifiable limit. As previously reported, 
CBN levels were much higher than commonly found in sinsemilla (min, 0.9%; max, 2.9%; median, 
2.7%). The high CBN content, relative to THC, suggests excessive THC degradation during processing 
and a lengthy journey to the UK.  
 
Potency of trichome powders in herb grinders 
 
The trichome powders were the most potent samples analyzed in this study, containing 46.0% and 
34.3% THC with 0.7% and 0.3% CBN, respectively. A level of 0.2% CBD was detected in the first but 
the level was below the quantifiable limit in the latter. 
Cannabinoid content of resin 
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Resin samples showed an even wider variation in THC content than that seen with sinsemilla. This 
finding was accompanied by widely varying CBD and CBN contents. In two samples, no cannabinoids 
were detected. These were excluded from the statistical analysis. Several others had total 
measurable cannabinoid contents of less than 1%. In the 2005 study, the maximum THC content 
observed was 10.8%. In this latest study, a quarter of samples exceeded that value, the most potent 
exceeding 29% THC. This sample was one of two resin samples seized in a prison, where the high 
potency facilitated the smuggling of high quantities of THC in minimal volume. One notable street 
sample contained 11% CBD, but all others contained 6% or less.  
 
The THC:CBD:CBN ratios of individual samples in the 2005 and 2016 studies are compared 
graphically in Figure 3. These data were analyzed using the Kolmogorov–Smirnov test for different 
distributions, which showed that the two distribution patterns for 2005 and 2016 were significantly 
different (p < 0.0001). A Wilcoxon Rank-Sum test showed that the mean potency levels in 2016 (6.3% 
THC) were significantly higher (p < 0.0001) than those in 2005 (3.7% THC). Similar significance levels 
were observed for the drop in mean CBD content from 4.3% to 2.3%. As a consequence, the change 
in mean THC:CBD ratio from 0.8:1.0 to 2.7:1.0 was also highly significant (p < 0.0001). The difference 
in mean CBN content of resin in 2005 (1.7%) and 2015 (1.3%) was not significant (p = 0.10). 
 
Unlike sinsemilla, where visual examination gave some indication of likely cannabinoid content, the 
appearance of small cannabis resin samples gave minimal indication. This observation is illustrated in 
Figure 4, which shows a selection of 15 of the samples. Accompanying this, Table 3 shows the %THC, 
CBD, and CBN of each. 
 
The high THC content of the resin powders in the grinders illustrated the ability of sieving systems to 
produce potent materials lacking CBD. In the Netherlands, where a significant proportion of cannabis 
circulating has been purchased legally in regulated coffee shops, much of the resin is so-called 
“Nederhasj” and contains high levels of THC and minimal levels of CBD. It is made using entirely 
high-THC chemotype sinsemilla as the starting material.
29
 A range of equipment is available to wet or 
dry sieve cannabis for resin production. The starter material for this process is usually the waste 
material left when sinsemilla is manicured.
28(p38)
 However, sieving devices are reported to have been 
used in Morocco to produce potent resins.
30
 In the UK, it is possible that this sieving is only 
widespread among producers for personal use.  
 
Only 3 of the 54 samples in this study contained THC and no detectable CBD. This finding suggests 
that the majority of the resin samples were produced oversees, in locations where CBD-chemotype 
cannabis are common.  
 
Effect of aging on cannabinoid levels 
 
Mean CBN levels in sinsemilla samples were very low, despite the samples having often aged in 
police stores for many months before analysis. However, the THC content of resin is reported to be 
much less stable than that of sinsemilla. Atmospheric exposure of THC causes oxidation to CBN and 
other degradants. Martone and Della Casa
31
 showed that, even when stored in the dark, the half-life 
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of THC was often less than 1 year, and in some cases, THC had disappeared almost completely within 
2 years.  
 
For those samples in this study, where the exact the length of time in police storage was available 
(n=34), a regression calculation was performed to determine any correlation between the level of 
CBN formation and the length of time spent in storage prior to the sample being deep frozen. In a 
scatter plot (not shown), the regression line was almost horizontal, highlighting that no meaningful 
correlation existed between storage date and the proportion of CBN. The regression model can be 
summarized as: 
CBN as % of THC+CBN total = 0.0109x + 21.257 * Weeks in storage (p = 0.956977, R
2
 = 9.24E-05). 
Police evidence bags are designed to have an excellent seal, thereby protecting police officers 
against accusations of tampering with evidence. This design has protected the resin from oxidative 
degradation. The cannabinoid levels detected are therefore a fair reflection of those existing at the 
time the samples were seized. 
 
Cannabis concentrates 
 
Two samples of hash oil were provided by constabularies not included within this main study. Both 
contained 51% THC and less than 1% CBD. A few forms of BHO were provided, described as wax, 
wax-crumble, or shatter. These contained between 73% and 83% THC, with less than 1% CBD. These 
analyses are reported here for interest. 
 
Implications for pharmacology 
 
Δ
9
–THC is the main ingredient in cannabis affecting perception, mood, emotion, and cognition that 
together constitute the psychotropic effect.
32 
This effect is linked to its interaction with two G 
protein-coupled receptors named cannabinoid receptor types 1 (CB1) and 2 (CB2). CB1 receptors are 
found in brain and nerve tissue and their activation can, among other things, beneficially control 
motor function and induce signs of analgesia. CB2 receptors are found within the immune cells. 
Although less well understood, their activation can lead to cytokine release inside and outside the 
brain.
33
 Only four of the many cannabinoids found in cannabis are known to interact with these 
receptors, viz Δ
9
–THC, Δ
8
–THC, Δ
9
–tetrahydrocannabivarin (i.e., THCV) and CBN. Δ
8
–THC was not 
found in quantifiable amounts in any of the samples in this study, and Δ
9
–THCV never exceeded 0.2% 
w/w. It is unlikely that these two cannabinoids could have majorly affected the pharmacologic 
activity of the samples. CBN binds less potently to CB1 and CB2 receptors than Δ
9
–THC, but as it was 
frequently present in substantial quantities, especially in resin and imported herbal material, it 
therefore had the potential to impart some pharmacological effect. CBD lacks psychotropic activity 
but has markedly different therapeutic potential to Δ
9
–THC, offering potential management of 
inflammation, anxiety, emesis, and nausea. It also offers neuroprotective and antioxidant activity.
33 
 
In all but one case, the 400 sinsemilla samples were devoid of CBD, as were the few imported herbal 
samples, and they therefore lacked the pharmacologic qualities that this ingredient might otherwise 
offer. Due to its antipsychotic activity, CBD also has the potential to reduce the onset or degree of 
the psychoactive effects of THC.
23
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 CBD was present in resin samples, but in widely varying ratios with THC. This finding would be 
expected to greatly affect the range of medical conditions that might benefit from cannabis 
administration, as well as the magnitude of effect. This predicted variability in efficacy of THC+CBD 
mixtures is exacerbated by evidence that THC and CBD act together synergistically.
34
 When drugs 
demonstrate synergy, even small variations in ingredient ratio can have a relatively large effect on 
overall activity.  
 
CBN is a degradant of THC and is less pharmacologically active. Its presence therefore indicates that 
THC and overall activity may have been reduced. In some cases, however, the loss of THC will have 
beneficially reduced the potential for psychoactive effects while, at the same time, increasing the 
CBD:THC ratio.  
 
Due to the reduction in relative availability of resin compared with sinsemilla since the last cannabis 
potency studies, the overall proportion of CBD within the available cannabis market has been 
significantly reduced. Much of the efficacy and protection from some of the adverse effects of THC 
has been lost.  
 
Licenced medicines in the Western world are expected to meet specified levels of quality, safety, 
and efficacy. Apart from highlighting the variable protection from psychoactive adverse effects, this 
article does not address the safety issues but acknowledges that microbial, pesticide, and heavy 
metal residues as well as adulterants are frequently present in herbal products where quality has not 
been managed. 
 
Implications for mental health 
 
Rising THC levels and disappearing CBD levels have the potential to impact the number of cannabis 
users at risk of developing psychotic disorders.
35 
 Consistently, epidemiological evidence has shown 
that the strength of the association between cannabis use and the increased risk of psychotic 
disorder is dose-response related. High-potency cannabis carries the greatest risk.
35 
Moreover, 
several experimental studies demonstrated that the administration of tetrahydrocannabinol, the 
active ingredient of cannabis, can induce transient psychosis in healthy volunteers and this effect can 
be dampened by coadministration of cannabidiol.
36 
 
More recently, clear evidence has shown that the risk of developing a psychotic disorder or 
experiencing psychotic symptoms after cannabis use is related to: (1) the THC 
content of the cannabis, and (2) a THC:CBD ratio in that cannabis of >1. 
35, 37
 Moreover, the use of 
types of cannabis with a THC:CBD ratio of ≤1  is not associated with an increase in the risk of 
psychosis.
35 
 
 
Although we reported that the THC content of sinsemilla has remained stable in England over the 
past 11 years, the decreasing availability of resin (the only reliable source of CBD) has reduced the 
overall proportion of CBD within the cannabis market. Moreover, our findings indicate that, in the 
few available resin samples, the average THC content has significantly increased whereas average 
CBD content has decreased compared to those of samples analyzed in 2005,
9
 pointing at a cannabis 
street market dominated by high-potency varieties.  
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Self-titration, or smoking less when using high--potency cannabis, has been suggested by some as a 
method for potentially counteracting the impact of high-potency cannabis use. Although this 
method may be used by experienced adult users, no published data suggest this approach is 
common among young adolescents, who are the most vulnerable group in terms of experiencing 
psychosis associated with cannabis use.
38
 
Finally, data from the United States on the impact of widespread changes to cannabis legislation are 
becoming available. An article recently published by Hasin et al indicated that, in US states such has 
California that have passed medical marijuana laws, both an increased prevalence of illicit cannabis 
use and, more importantly, of cannabis use disorders has been noted. The authors concluded that, 
“While medical marijuana may help some, cannabis-related health consequences associated with 
changes in state marijuana laws should receive consideration by health care professionals and the 
public.”
39
 
 
Recommendation 
 
Although the potency and cannabinoid profile of sinsemilla appears to have remained unchanged 
over the past decade, the cannabinoid profile of resin circulating in England appears to be following 
the trend observed in France. This trend presents an increased risk of harm to those susceptible to 
the development of psychotic disorders following cannabis use. Future effort should be invested in a 
larger nationwide survey, which focuses on the distribution and cannabinoid content of resins and 
the cannabis oils and concentrates now starting to appear. 
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Figure 1. Range of sinsemilla THC contents in Derbyshire, Kent, London Metropolitan, Merseyside and 
Sussex in 2004/2005 (n = 247) and 2015/2016 (n = 400).  
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Figure 2. The %THC content of samples in each constabulary area, displayed in ascending potency.  
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Figure 3. The varying THC:CBD:CBN ratios in illicit cannabis analyzed in 2005 and 2016.  
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Figure 4. A selection of 15 illicit resin samples from 2016. A sample made on a police drug expert witness 
training event (bottom right) is included for comparison. Samples are shown in order of increasing THC 
content from top left to bottom right.  
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Table 1. The Agilent 7890A Sample Preparation Program 
 
 Rate °C/min Value °C Hold Time (min) Run time (min) 
(Initial)  60 3 2 
Ramp 1 35 200 0 6 
Ramp 2 5 250 5 21 
Ramp 3 100 320 3.3 25 
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Table 2. Sample number in each constabulary region in each of three studies, 2005, 2008, and 2016. 
 
  No. (% of Total) 
Year Type London Kent Sussex Merseyside Derbyshire Total 
        
2016 Sinsemilla 349     (95.9) 309     (94.5) 90        (85.7) 81        (87.1) 100       (96.2) 929     (93.6) 
 Traditional 5            (1.4) 0            (0.0) 0            (0.0) 0            (0.0) 1              (1.0) 6            (0.6) 
 Resin 10          (2.7) 18          (5.5) 15        (14.3) 12        (12.9) 3              (2.9) 58          (5.8) 
 Total 364 327† 105 93 104 993† 
        
2008 Sinsemilla  255     (93.1) 96        (82.8) 113     (80.7) 182     (82.0) 62         (83.8)   708    (84.5) 
 Traditional  11          (4.0)    2         (1.7)   1          (0.7)  0          (0.0)  0            (0.0)   14        (1.3) 
 Resin   8           (2.9)   18      (15.5)   26      (18.6)  40      (18.0)  12        (16.2)   104    (14.2) 
 Total  274  116 140 222 74 826 
        
2005* Sinsemilla 96          (61.0) 58        (41.8) 34       (65.4) 44             (-)  15        (34.1) 247      (50.6) 
 Traditional 30          (18.9) 0            (0.0) 3           (5.6) 1               (-)  1             (2.3)  35         (6.7) 
 Resin 32          (20.1) 85        (59.4) 15       (28.8) 9               (-)  28         (63.6)  169     (42.7) 
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 Total 158 143‡ 52 54 44 451‡ 
 
* Resin samples in Merseyside in 2005 were latterly added. True proportion would have been higher. 
† In addi.on to the totals shown in 2016, there were 2 trichome resin powders from Kent. 
‡ In addi.on to the totals shown in 2005, there was 1 trichome resin powder from Kent. 
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Table 2. Comparison of THC, CBD and CBN contents (% w/w) of the range of resin samples within the 
potency study, illustrated in Figure 4. 
 
Sample Number %THC  %CBD  %CBN 
1   0.0  0.0  0.0 
2   0.4  0.5  0.3 
3   1.6  1.8  4.2 
4   2.2  0.9  0.4 
5   3.6  1.1  1.2 
6   3.9  2.9  1.5 
7   4.0  2.6  1.2 
8   5.6  2.5  1.5 
9   10.6  4.2  1.9 
10   10.8  1.8  1.7 
11   11.8  11.3  1.9 
12   12.1  4.4  1.7 
13   15.5  2.3  1.2 
14   25.7  2.8  0.9 
15   29.3  3.0  1.1 
16*   41.0  0.6  1.0  
* All samples are from the 2016 potency study, except sample 16, which was made during a 
police drug expert training event. 
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Figure 1. Range of sinsemilla THC contents in Derbyshire, Kent, London Metropolitan, Merseyside and 
Sussex in 2004/2005 (n = 247) and 2015/2016 (n = 400). 
 
Figure 2. The %THC content of sinsemilla samples in each constabulary area, displayed in ascending 
potency. 
 
Figure 3. The varying THC:CBD:CBN ratios in illicit cannabis analyzed in 2005 and 2016. 
 
Figure 4. A selection of 15 illicit resin samples from 2016. A sample made on a police drug expert 
witness training event (bottom right) is included for comparison. Samples are shown in order of 
increasing THC content from top left to bottom right. 
 
 
 
Table 1. The Agilent 7890A Sample Preparation Program 
 
 
Table 2. Sample number in each constabulary region in each of three studies, 2005, 2008, and 2016. 
 
Table 23. Comparison of THC, CBD and CBN contents (% w/w) of the range of resin samples within 
the potency study, illustrated in Figure 4. 
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